Similar articles for PMID: 22199312

Year	Number of Results
1986	1
1988	1
1990	1
1994	1
1998	2
1999	3
2001	1
2002	4
2003	6
2004	9
2005	10
2006	15
2007	16
2008	21
2009	22
2010	21
2011	28
2012	20
2013	18
2014	10
2015	17
2016	16
2017	13
2018	10
2019	4
2020	7
2021	2
2022	1
2023	2
2024	0

1

Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).

Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J. Wöll E, et al. Anticancer Res. 2011 Dec;31(12):4439-43. Anticancer Res. 2011. PMID: 22199312 Clinical Trial.

2

Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).

Wöll E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J. Wöll E, et al. Anticancer Res. 2008 Sep-Oct;28(5B):2901-5. Anticancer Res. 2008. PMID: 19031932 Free article. Clinical Trial.

3

Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.

Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P. Schønnemann KR, et al. Eur J Cancer. 2012 Mar;48(4):510-7. doi: 10.1016/j.ejca.2011.12.005. Epub 2012 Jan 12. Eur J Cancer. 2012. PMID: 22244801 Clinical Trial.

4

Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.

Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL Jr, Boehm KA, Asmar L. Cartwright T, et al. Clin Colorectal Cancer. 2008 Nov;7(6):390-7. doi: 10.3816/CCC.2008.n.052. Clin Colorectal Cancer. 2008. PMID: 19036692 Clinical Trial.

5

Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.

Tahara M, Shirao K, Boku N, Yamaguchi K, Komatsu Y, Inaba Y, Arai T, Mizunuma N, Satoh T, Takiuchi H, Nishina T, Sakata Y. Tahara M, et al. Jpn J Clin Oncol. 2008 Nov;38(11):762-9. doi: 10.1093/jjco/hyn102. Epub 2008 Oct 4. Jpn J Clin Oncol. 2008. PMID: 18836202 Clinical Trial.

6

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd. Sobrero AF, et al. J Clin Oncol. 2008 May 10;26(14):2311-9. doi: 10.1200/JCO.2007.13.1193. Epub 2008 Apr 7. J Clin Oncol. 2008. PMID: 18390971 Clinical Trial.

7

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.

Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L. Richards D, et al. Eur J Cancer. 2013 Sep;49(13):2823-31. doi: 10.1016/j.ejca.2013.04.022. Epub 2013 Jun 5. Eur J Cancer. 2013. PMID: 23747051 Clinical Trial.

8

Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.

Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Agostara B, Barone C. Gebbia V, et al. Clin Colorectal Cancer. 2006 Mar;5(6):422-8. doi: 10.3816/CCC.2006.n.013. Clin Colorectal Cancer. 2006. PMID: 16635281 Clinical Trial.

9

Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution.

Shi M, Ji J, Wu J, Ma T, Liu Y, Zhou CF, Su Y, Ye ZB, Zhang J, Zhu ZG. Shi M, et al. Hepatogastroenterology. 2012 Jun;59(116):1054-8. doi: 10.5754/hge11874. Hepatogastroenterology. 2012. PMID: 22281975

10

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M. Assenat E, et al. Oncologist. 2011;16(11):1557-64. doi: 10.1634/theoncologist.2011-0141. Epub 2011 Oct 20. Oncologist. 2011. PMID: 22016477 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

248 results

Results by year